Phase 1, Investigator And Subject-Blind, Placebo-Controlled, Randomized, Sequential Group, Multiple Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-04802540 In Patients With Schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2010
At a glance
- Drugs TS 032 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 14 Oct 2009 Actual patient number (39) added as reported by ClinicalTrials.gov.
- 14 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 May 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.